Synthetic VNAR Library for High-Affinity Antibody Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing therapeutic antibodies, particularly using shark-derived IgNARs, face challenges such as limited diversity, low affinity, and the need for animal immunization, which complicates the isolation of high-affinity, specific binders.
Innovation Solution
A synthetic library of antigen-specific binding molecules is created by fusing different VNAR sequences from various Elasmobranchii species, incorporating diverse CDR and framework regions, and using directed mutagenesis to enhance diversity, resulting in a library size of over 9×10^10 clones, allowing for high-throughput selection of binders without animal immunization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional animal immunization methods are used to generate shark-derived IgNARs, then specific antigen binding molecules can be obtained, but the process is complicated and time-consuming with limited diversity
Solution Approach 1:
The patent applies preliminary action by pre-assembling VNAR domains from diverse shark species frameworks and CDR regions before immunization. This creates a synthetic library that is ready for rapid screening, eliminating the need to generate antibodies from scratch through traditional immunization processes. The synthetic library approach allows direct selection of high-affinity binders without waiting for animal immune responses.
Solution Approach 2:
The patent uses copying by creating synthetic replicas of natural VNAR structures through combinatorial assembly of framework regions and CDRs from multiple shark species. Instead of relying on a single animal immune response, the invention copies and recombines successful binding motifs from diverse sources to generate a library that captures a broader range of specificities and affinities.
2Adaptability or versatility
If synthetic libraries are created to increase diversity, then library size increases to over 9×10^10 clones, but the complexity of library construction increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into separate functional modules: framework regions from different shark species and CDR regions that provide binding specificity. These segments are independently optimized and then assembled through standardized interfaces, allowing complex diversity to be generated from simpler, well-characterized components. This modular approach manages construction complexity while maximizing diversity.
Solution Approach 2:
The patent uses merging by combining framework regions and CDR regions from multiple shark species into unified VNAR sequences. The synthetic library merges diverse genetic sources through controlled recombination, integrating the stabilizing frameworks from different species with the antigen-binding CDRs to create chimeric molecules that exhibit both structural stability and diverse specificities.
3Reliability
If traditional single-domain scaffolds are used, then therapeutic candidates can be developed, but affinity and efficacy are limited compared to diversified libraries
Solution Approach 1:
The patent applies composite materials by creating chimeric VNAR molecules that combine framework regions from different shark species (providing structural stability) with CDR regions that provide binding specificity. This composite approach merges the advantageous properties of different natural antibodies into single molecules, achieving both high affinity and diverse specificity that neither source could provide alone.
Data Source
AI summary
The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules. The invention also provides methods for the production of an antigen specific antigen binding molecule as defined, pharmaceutical compositions comprising such molecules and uses thereof in medicine.